-+ 0.00%
-+ 0.00%
-+ 0.00%

Apnimed Q3 Net Loss More Than Doubles to $29.52 Million

PUBT·11/16/2026 13:02:00
Listen to the news
Apnimed Q3 Net Loss More Than Doubles to $29.52 Million
  • Apnimed’s third-quarter net loss more than doubled year over year to $29.52 million.
  • Related-party revenue fell 72% to $2.48 million, while general and administrative expenses more than tripled to $22.63 million.
  • Cash and cash equivalents totaled $351.8 million at September 30, 2026, expected to fund operations into the second quarter of 2028.
  • The FDA continues reviewing AD109 for obstructive sleep apnea, with a February 28, 2027, decision goal date.
  • Commercial preparations advanced for a potential US launch of AD109, proposed brand name Oxnimbi, subject to FDA approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9877674) on November 16, 2026, and is solely responsible for the information contained therein.